New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Chrissy Teigin is the new face of Sanofi’s diabetes campaign. 1 The educational campaign is called Screen for Type 1, and it ...

Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical ...

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...